Clinical Trial Update: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CVL-865 as adjunctive therapy for focal onset seizures has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Seizures

Drugs mentioned

• CVL-865

Snippet

Sponsor: AbbVie | Conditions: Seizures | Phase 2 | Status: COMPLETED | Results posted: 2025-05-30